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It has been a few decades since the 
proposal by Blaustein et al. that high 
salt intake is linked to contraction of 
vascular smooth muscle and hence 
to hypertension. According to this 
idea, high salt intake increases the 
production of an endogenous ouabain-
like compound that blocks the Na,K-
ATPase. Th e consequent increase in 
cell sodium causes an infl ux of calcium 
via the Na/Ca exchanger, leading to 
high cell calcium and consequent 
smooth muscle contraction, increased 
peripheral vascular resistance, and 
hypertension. In this issue of Kidney 
International, Iwamoto and Kita discuss 
the new evidence for this hypothesis 
based on the cloning of a family of 
genes that mediate Na/Ca exchange. 
Th e development of specifi c inhibitors 
of vascular Na/Ca exchangers led to 
the appearance of salt-dependent 
hypertension. Similarly, the deletion of 
the vascular Na/Ca exchanger type 1 
also led to the development of salt-
dependent hypertension. When the 
Na,K-ATPase was replaced with another 
one that has a mutation that lowers its 
affi  nity for ouabain, it removed the salt 
sensitivity of the hypertension. Th ese 
studies have rejuvenated the interest in 
this hypothesis that attempts to make 
a direct link between salt intake and 
blood pressure regulation. See page 
2148.
Pseudohypoaldostero-
nism, WNK kinase, and 
Na:Cl cotransporter 
function
Pseudohypoaldosteronism type II is 
a mendelian form of hypertension 
in which it appeared that there is an 
increase in the absorption of NaCl in 
the distal convoluted tubule. When the 
gene was identifi ed, it turned out to 
encode a protein kinase of unknown 
function, called WNK; two of these 
kinases have been associated with 
the disease. Th e protein is expressed 
in the distal tubule cell near the tight 
junction. One possible function of 
these kinases is to regulate the anion 
permeability of the tight junction. 
Another possible mechanism is 
that the kinase controls the level of 
expression of the Na:Cl cotransporter 
on the apical membrane of the distal 
tubule. Previous studies had suggested 
that WNK4 might do this in Xenopus 
oocytes. As they report in this issue, 
Cai et al. examined this matter in 
a mammalian cell and found that 
WNK4 signifi cantly reduced the 
surface expression of the transporter. 
Hence, mutants that lack the kinase 
function would be expected to increase 
the surface expression and therefore 
increase the fl ux of NaCl absorption 
in the distal tubule. Preliminary 
studies suggested that WNK4 and the 
transporter protein directly interacted, 
whereas a mutant of WNK4 lacking 
kinase function did not. How does 
the kinase lead to a decreased surface 
expression? One possibility is that the 
WNK kinase causes the transporter 
to be endocytosed and carried to the 
lysosomes, where it is degraded. In 
favor of this hypothesis, the authors 
found that blockade of lysosomal 
degradation increased surface 
expression. See page 2162.
Vasopressin receptor 
antagonists
Th e antidiuretic hormone vasopressin 
binds to two classes of receptors; one is 
responsible for its eponymic eff ect — 
that is, to increase vascular resistance. 
Th e other receptor, present in the 
collecting duct, causes an increase 
in water permeability of the tubule. 
Th e development of blockers of this 
receptor would be expected to reduce 
urine concentration and increase 
water diuresis. In clinical conditions 
associated with hyponatremia, such 
as the syndrome of inappropriate 
antidiuretic hormone secretion, the 
only available treatment is water 
restriction, which is oft en diffi  cult to 
enforce. Recent identifi cation of small-
molecule blockers of this receptor 
are now in clinical development, 
and in this issue, Greenberg and 
Verbalis present the clinical evidence 
of effi  cacy. Clinical trials indicate 
that these agents, as expected, reduce 
urine osmolality, increase free water 
excretion, and raise serum sodium 
concentration. Also as expected, their 
use increases thirst, which might 
eventually limit their eff ectiveness. 
Regardless, these drugs should prove 
useful for the treatment of acute and 
life-threatening hyponatremia. But 
more extended and long-term studies 
will need to be conducted to evaluate 
their use. It had also been suggested 
that they may be useful in slowing 
the progression of polycystic kidney 
disease, and such trials are also awaited 
with interest. See page 2124.
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